Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytodyn Inc (OP: CYDY )

0.1169 UNCHANGED
Streaming Delayed Price Updated: 3:57 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.1169
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1169
Today's Range 0.1169 - 0.1169
52wk Range 0.1050 - 0.4180
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire

Performance

YTD
-40.66%
-40.66%
1 Month
-8.31%
-8.31%
3 Month
-16.56%
-16.56%
6 Month
-48.00%
-48.00%
1 Year
-23.14%
-23.14%

More News

Read More
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
From CytoDyn Inc.
Via GlobeNewswire
September 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Engages Leading CRO For Phase II Inflammation Trial
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Settlement with Amarex Clinical Research LLC
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn to Host Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
May 2024 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces FDA Has Lifted Clinical Hold
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Webcast to Provide Company Update
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO
From CytoDyn Inc.
Via GlobeNewswire
November 2023 Letter to Shareholders
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces Company Updates and Investment Community Update Webcast
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn Announces President Takes Medical Leave of Absence
From CytoDyn Inc.
Via GlobeNewswire
CytoDyn to Hold Webcast to Provide a Company Update
From CytoDyn Inc.
Via GlobeNewswire
Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
Via Benzinga
CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
From CytoDyn Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.